Defining the risk of SARS-CoV-2 variants on immune protection

MM DeGrace, E Ghedin, MB Frieman, F Krammer… - Nature, 2022‏ - nature.com
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …

The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology

BB Oude Munnink, N Worp, DF Nieuwenhuijse… - Nature medicine, 2021‏ - nature.com
The current coronavirus disease 2019 (COVID-19) pandemic is the first to apply whole-
genome sequencing near to real time, with over 2 million severe acute respiratory syndrome …

Population immunity and Covid-19 severity with Omicron variant in South Africa

SA Madhi, G Kwatra, JE Myers, W Jassat… - … England Journal of …, 2022‏ - Mass Medical Soc
Abstract Background The B. 1.1. 529 (omicron) variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) was first identified on November 25, 2021, in Gauteng …

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

S Feng, DJ Phillips, T White, H Sayal, PK Aley, S Bibi… - Nature medicine, 2021‏ - nature.com
The global supply of COVID-19 vaccines remains limited. An understanding of the immune
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …

Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses

T Mao, B Israelow, MA Peña-Hernández, A Suberi… - Science, 2022‏ - science.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
highlighted the need for vaccines that not only prevent disease but also prevent …

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim …

SA Madhi, AL Koen, A Izu, L Fairlie, CL Cutland… - The Lancet …, 2021‏ - thelancet.com
Background People living with HIV are at an increased risk of fatal outcome when admitted
to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to …

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern

L Dupont, LB Snell, C Graham, J Seow, B Merrick… - Nature …, 2021‏ - nature.com
COVID-19 vaccine design and vaccination rollout need to take into account a detailed
understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 …

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants

C Liu, D Zhou, R Nutalai, HME Duyvesteyn… - Cell Host & Microbe, 2022‏ - cell.com
Summary Alpha-B. 1.1. 7, Beta-B. 1.351, Gamma-P. 1, and Delta-B. 1.617. 2 variants of
SARS-CoV-2 express multiple mutations in the spike protein (S). These may alter the …

[HTML][HTML] Structural evaluation of the spike glycoprotein variants on SARS-CoV-2 transmission and immune evasion

MZ Salleh, JP Derrick, ZZ Deris - International journal of molecular …, 2021‏ - mdpi.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents
significant social, economic and political challenges worldwide. SARS-CoV-2 has caused …

Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity

CM Zu Natrup, A Tscherne, C Dahlke… - The Journal of Clinical …, 2022‏ - jci.org
The SARS-CoV-2 spike (S) glycoprotein is synthesized as a large precursor protein and
must be activated by proteolytic cleavage into S1 and S2. A recombinant modified vaccinia …